Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02058901
Recruitment Status : Completed
First Posted : February 10, 2014
Last Update Posted : July 17, 2019
Sponsor:
Information provided by (Responsible Party):
H.M.W. Verheul, VU University Medical Center

Brief Summary:

The primary objective of this study is:

  • To determine the maximum tolerated dose (MTD) of sunitinib when administered once weekly or once every two weeks.
  • To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: Sunitinib Phase 1

Detailed Description:
Our hypothesis is that sunitinib, when given in a high-dose, intermittent schedule may exhibit improved efficacy with an acceptable toxicity profile. In the present phase I trial, we aim to determine the maximum tolerated dose of sunitinib when administered high-dose, once weekly or once every two weeks. Furthermore, by acquiring skin and tumor biopsies, we will assess intratumoral concentrations of sunitinib, correlate these to skin and plasma concentrations and gain more insight into the biological effects of the drug. Additionally, we aim to preliminary assess the efficacy of sunitinib administered at the MTD level in both schedules. Known serum angiogenesis markers will be correlated to efficacy endpoints.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 101 participants
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
Study Start Date : July 2013
Actual Primary Completion Date : June 2019
Actual Study Completion Date : June 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sunitinib high dose, weekly schedule
Initial dose of sunitinib is set at 200 mg once weekly. Three patients are treated at the current dose level. If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
Drug: Sunitinib
Experimental: Sunitinib high dose, biweekly schedule
When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
Drug: Sunitinib



Primary Outcome Measures :
  1. maximum tolerated dose (MTD) of sunitinib [ Time Frame: 6 weeks ]
  2. Number of participants with serious and non-serious adverse events [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Calculation of maximum plasma drug concentration, sunitinib half life, Area Under the Concentration-Time Curve (AUC 0-48h), clearance and volume of distribution [ Time Frame: Prior to the initial dose on day 1 and 2, 4, 6, 8, 10, 24, and 48 hours post-dose ]
  2. Time to Disease Progression [ Time Frame: end of study ]
  3. Recommended phase II dose (RP2D) and the optimal dose schedule [ Time Frame: End of study ]
  4. Measurement of intratumoral and skin concentration of sunitinib [ Time Frame: 2 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed (by the patient or legally acceptable representative) and dated Informed Consent Form
  • Histological or cytological documentation of incurable locally advanced or metastatic solid malignancy for which no standard therapy exists.
  • Primary tumor or metastatic site must be accessible for biopsy. Patients eligible for the expansion cohort must be willing to undergo tumor biopsies, while tumor biopsy remains optional for patients enrolled in the escalation cohort. Bone metastases are excluded as a biopsy site.
  • Evaluable disease by RECIST version 1.1 criteria (see appendix III; at least 1 target or non-target lesion for dose escalation cohorts; at least 1 target lesion for dose expansion cohort).
  • Patients must have documented radiographic or clinical progressive disease.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Normal 12-lead ECG (clinically insignificant abnormalities permitted), and Left Ventricular Ejection Fraction (LVEF) > 50% by multigated acquisition (MUGA) scan or echocardiogram.
  • Normal regulated thyroid function- suppletion or blocking drugs permitted.
  • Urinalysis: no clinically significant abnormalities.
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening:

    1. Hemoglobin >= 5.6 mmol/l
    2. Absolute neutrophil count (ANC) >=1,5 x 10*9/l
    3. Platelet count >= 100 x 10*9/l
    4. Total bilirubin <=1.5 times the upper limit of normal (ULN)
    5. ALT and AST 2.5 x ULN (In case of liver metastases: < 5 x ULN)
    6. Alkaline phosphatase < 4 x ULN
    7. Serum creatinine <= 1.5 x ULN or Creatinine clearance >= 50 ml/min (based on MDRD)
    8. PT-INR/PTT < 1.5 x ULN, unless coumarin derivatives are used
    9. Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed, if this treatment can be interrupted for a biopsy as judged by the treating physician)
  • Patients with known Gilbert's disease who have serum bilirubin <= 3x ULN may be enrolled.
  • Pregnant or breast-feeding subjects: Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. For fertile men or women of childbearing potential: documented willingness to use a highly effective means of contraception (e.g., hormonal methods [implants, injectables, or combined oral contraceptives], intrauterine devices, sexual abstinence, or vasectomized or surgically sterilized partner). Contraception is necessary for at least 6 months after receiving the study kinase inhibitor.

Exclusion Criteria:

  • Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture.
  • Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements.
  • Seizure disorders requiring anticonvulsant therapy.
  • jor surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery.
  • Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.)
  • Known hypersensitivity to sunitinib or to its excipients.
  • Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patient's compliance.
  • Drug or alcohol abuse.
  • Females who are pregnant or breast-feeding.
  • Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications.
  • Unwillingness or inability to comply with study and follow-up procedures.
  • No chemotherapy, radiotherapy, or biologic therapy within the previous 4 weeks; no nitrosoureas or mitomycin C within the previous 6 weeks; no investigational agents within the previous 4 weeks.
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
  • Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control);
  • Patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met:

    1. Presence of evaluable or measurable disease outside the CNS
    2. Radiographic demonstration of improvement upon completion of CNS-directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study
    3. Completion of radiotherapy ≥ 8 weeks prior to the screening radiographic study
    4. Discontinuation of corticosteroids and anticonvulsants ≥ 4 weeks prior to the screening radiographic study.

Note: Prior sunitinib therapy does not constitute an exclusion criterion.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02058901


Locations
Layout table for location information
Netherlands
VU University Medical Center
Amsterdam, Netherlands, 1081HV
Sponsors and Collaborators
VU University Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Henk MW Verheul, MD, PhD VU University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: H.M.W. Verheul, Prof. Dr., VU University Medical Center
ClinicalTrials.gov Identifier: NCT02058901     History of Changes
Other Study ID Numbers: 2013/75
2012-005756-41 ( EudraCT Number )
First Posted: February 10, 2014    Key Record Dates
Last Update Posted: July 17, 2019
Last Verified: July 2019
Keywords provided by H.M.W. Verheul, VU University Medical Center:
sunitinib
solid tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Sunitinib
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action